CSL strikes up to $1.6B deal with Alentis for autoimmune drug with broad potential

Summary

CSL has entered a co-development and co-promotion agreement with Alentis Therapeutics valued at up to $1.6B for lixudebart, an anti-claudin-1 therapy targeting kidney and liver conditions including primary sclerosing cholangitis and systemic autoimmune disease.